Ocular Toxoplasmosis: Controversies in Primary and Secondary Prevention | OMICS International | Abstract
E-ISSN: 2314-7326
P-ISSN: 2314-7334

Journal of Neuroinfectious Diseases
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Ocular Toxoplasmosis: Controversies in Primary and Secondary Prevention

Norman A. Saffra1,2*, Carly J. Seidman1,2, and Louis M.Weiss3

1Division of Ophthalmology, Maimonides Medical Center, Brooklyn, NY 11219, USA

2Department of Ophthalmology, New York University, New York, NY 10016, USA

3Departments of Medicine and Pathology, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY 10461, USA

*Corresponding Author:
Norman A. Saffra
Division of Ophthalmology
Maimonides Medical Center
Brooklyn, NY 11219
E-mail: [email protected]

Received date: 6 January 2013; Accepted date: 23 February 2013

Copyright: © 2013 Norman A. Saffra et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Ocular toxoplasmosis is the most common cause of posterior uveitis in the United States and worldwide. It commonly follows a relapsing course with the potential for multiple adverse visual sequelae and, rarely, blindness. Both immune-competent and immune-suppressed populations can develop severe relapsing disease. There is considerable debate regarding the initial treatment of ocular toxoplasmosis in both groups, with multiple antiparasitic agents commonly used with little evidence to support any particular regimen. The precise role of corticosteroids in treatment also has yet to be rigorously defined. Secondary prevention is commonly implemented in the immune suppressed population, but there is a lack of level one evidence to support its role in immune-competent patients, though it warrants future investigation.